Skip to search formSkip to main contentSkip to account menu

avelumab

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

MSB0010718C

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.
TPS9 Background: Preclinical studies suggest that chemotherapy (CTX) and PARP inhibitors may increase tumor antigenicity… 
2018
2018
Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
2018
2018
Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma
Review
2017
Review
2017
Update of systemic immunotherapy for advanced urothelial carcinoma.
Review
2017
Review
2017
Immunotherapy for Triple-Negative Breast Cancer: A Focus on Immune Checkpoint Inhibitors
  • Isha Dua
  • 2017
  • Corpus ID: 3713929
Introduction Triple-negative breast cancer (TNBC) is clinically defined as breast tumors lacking expression of estrogen receptor… 
Highly Cited
2016
Highly Cited
2016
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.
8503Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple cancers. We report… 
Highly Cited
2016
Highly Cited
2016
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.
4009Background: Avelumab (proposed INN) is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple… 
2016
2016
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.
4514Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple cancers. We report… 
2016
2016
Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.
167 Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of… 
2016
2016
Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression
9036Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple cancers. We report… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)